FORMOSA LABORATORIES INCFF

FORMOSA LABORATORIES INC

73.9TWDD
+0.4+0.54%
As of today at 02:42 GMT
TWD
No trades
See on Supercharts

4746 fundamentals

Key facts

Market capitalization‪8.90 B‬TWD
Founded1995
CEOCheng Yue Cheng
About

Formosa Laboratories, Inc. engages in the research and development of biotechnology new drugs. It specializes in development, production, process, and sale of ultraviolet absorbers, cholesterol phosphate binders, vitamin D derivatives, anti-inflammatory analgesic, and central nervous system drugs. The company's products include active pharmaceutical ingredients, contract research and custom synthesis, integrated application delivery controller services, and ultraviolet filters for sunscreens and cosmetics. Formosa Laboratories was founded by Cheng Yu Cheng on December 29, 1995 and is headquartered in Taoyuan, Taiwan.

Ownership
‪‪120.26 M‬‬
Free Float shares
‪‪84.05 M‬‬ (69.9%)
Closely held shares
‪‪36.20 M‬‬ (30.1%)
Free Float shares
‪‪84.05 M‬‬ (69.9%)
Closely held shares
‪‪36.20 M‬‬ (30.1%)
Capital structure
Market cap
‪‪8.90 B‬‬
Debt
‪‪3.90 B‬‬
Minority interest
‪‪962.70 M‬‬
Cash & equivalents
‪‪2.70 B‬‬
Enterprise value
‪‪11.06 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪8.90 B‬‬
Price to earning ratio (P/E)
56.83x
Price to sales ratio (P/S)
1.88x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
56.83x
Price to sales ratio (P/S)
1.88x
Valuation ratios
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪60.00‬
‪120.00‬
‪180.00‬
‪240.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−9%‬
‪0%‬
‪9%‬
‪18%‬
‪27%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−500.00 M‬‬
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−500.00 M‬‬
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−500.00 M‬‬
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Active Pharmaceutical Ingredient
Other
By country
Period: 2024
Other
India
United States
Netherlands
Taiwan
Japan
Germany
China
Switzerland

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
‪‪1.40 B‬‬
Actual
Estimate
Earnings
Next:May 9, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.80‬
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
229.39%
Payout ratio (TTM)
Dividend yield TTM
2.70%
Last payment
2.00
Last ex-date
Aug 13, 2024
Dividend history
‪0.0%‬
‪1.1%‬
‪2.2%‬
‪3.3%‬
‪4.4%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−1.50 B‬‬
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪2.10 B‬‬
‪‪4.20 B‬‬
‪‪6.30 B‬‬
‪‪8.40 B‬‬
Assets
Liabilities